Pith Wave Signal

4 stories tagged #Boehringer Ingelheim

Newest Most read
  1. Boehringer's Obesity Drug Shows Promising Weight Loss, Flagging Tolerability Concerns
    health

    Boehringer's Obesity Drug Shows Promising Weight Loss, Flagging Tolerability Concerns

    Boehringer Ingelheim releases detailed phase 3 obesity drug data: 16.6% weight loss, significant liver fat reduction, but tolerability issues spark investor sell-off.

    2w ago 1 min read
  2. Pharma Giants Invest £450M in UK, Boosting Innovation
    health

    Pharma Giants Invest £450M in UK, Boosting Innovation

    AstraZeneca and Boehringer Ingelheim commit significant funds to UK expansion, focusing on research, AI, and new medicines.

    last mo. 1 min read
  3. Boehringer Ingelheim Obesity Drug Shows Significant Weight Loss in Phase 3 Trial
    health

    Boehringer Ingelheim Obesity Drug Shows Significant Weight Loss in Phase 3 Trial

    Boehringer Ingelheim's investigational obesity therapy, survodutide, achieved up to 16.6% average weight loss in a Phase 3 trial, targeting appetite and liver metabolism.

    2mo ago 1 min read
  4. Boehringer Ingelheim Releases Critical Insights on HER2 Mutations for Professionals
    health

    Boehringer Ingelheim Releases Critical Insights on HER2 Mutations for Professionals

    New educational resource outlines HER2 mutation impacts on receptor signaling and oncogenesis for US healthcare practitioners.

    3mo ago 1 min read